Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Explosive growth predicted in need for diabetes care products:

This article was originally published in Clinica

Executive Summary

Some 330 million people globally will be suffering from diabetes in 20 years' time. That is the stark prediction that was made on World Diabetes Day on November 12, as reported by Health First Europe. In the EU, the European Commission estimates that 19 million people, or 4% of the population are current affected by diabetes, and that this number is likely to increase to 26 million by 2030, or 6% of the population. In the EU, type-2 diabetes, which is often associated with obesity, costs some E15bn ($11.6bn) a year. The World Health Organisation estimates that the number of deaths attributed annually to diabetes is about 3.2 million, yet at least 50% of all people with diabetes are not aware of their life-threatening condition.

You may also be interested in...

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts